Attack reduction
Attack reduction Attack reduction by dose
An upclose photo of a neon sign. An upclose photo of a neon sign.

Efficacy An attack-free year is possible with DAWNZERA

Attack reduction

Switch: attack reduction

Substantial and sustained reductions in HAE attack rates1-3

  • Mean monthly HAE attack rate at Week 24 with DAWNZERA every 4 weeks was 0.44 vs 2.26 for placebo, an attack reduction of 81% (P<0.001, primary endpoint)1,2
  • This increased to an 87% reduction when measured from the second dose (0.30 vs 2.25 for placebo, P<0.001, secondary endpoint)1,2
Reductions in mean monthly HAE attack rate (investigator-confirmed) from baseline3
Neon lettering reading '~90'.
FEWER
moderate-to-severe HAE attacks*
Graph showing reductions in mean monthly HAE attacks rate over 1 year (investigator-confirmed) from baseline.
Graph showing reductions in mean monthly HAE attacks rate over 1 year (investigator-confirmed) from baseline.
*

Data cut off: January 27, 2025.3

Neon lettering reading '94'.
REDUCTION

at 1 year in the open-label study
across both DAWNZERA dosing arms3†

*

Data cut off: January 27, 2025.3

Placebo-controlled study results:

  • 53% of patients were attack free on DAWNZERA every 4 weeks (P=0.003 vs 9% with placebo)1,21†
  • DAWNZERA every 8 weeks reduced HAE attacks by 55% vs placebo (P=0.004)1†

†Secondary endpoint.1,3

Attack reduction by dose
DAWNZERA reduced attacks when taken every 4 or 8 weeks
DAWNZERA reduced moderate-to-severe HAE attacks,* HAE attacks requiring acute therapy,* and ER visits due to HAE attacks1,2†
Neon lettering reading 'fewer attacks'.
DAWNZERA every 4 weeks
DAWNZERA every 8 weeks

Reductions in HAE attack rates with DAWNZERA every 4 weeks (n=45)2

Bar chart showing mean monthly HAE attacks rates with DAWNZERA every 4 weeks. Bar chart showing mean monthly HAE attacks rates with DAWNZERA every 4 weeks.
Neon lettering reading '~90'.
FEWER
moderate-to-severe HAE attacks*

Reductions in HAE attack rates with DAWNZERA every 8 weeks (n=23)2.

Bar chart showing mean monthly HAE attacks rates with DAWNZERA every 8 weeks. Bar chart showing mean monthly HAE attacks rates with DAWNZERA every 8 weeks.
Neon lettering reading '~90'.
REDUCTION
in ER visits due to attacks2
ER=emergency room; LSM=least-squares mean; NR=not reported.
*Secondary endpoint.
†Exploratory endpoint.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.